US 12,221,468 B2
Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Anita Wiebe, Tuebingen (DE); Colette Song, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Aug. 26, 2021, as Appl. No. 17/412,932.
Application 17/412,932 is a continuation of application No. 17/229,682, filed on Apr. 13, 2021, granted, now 11,123,370.
Application 17/229,682 is a continuation of application No. 17/076,261, filed on Oct. 21, 2020, granted, now 11,058,726, issued on Jul. 13, 2021.
Application 17/076,261 is a continuation of application No. 16/911,028, filed on Jun. 24, 2020, granted, now 10,842,817, issued on Nov. 24, 2020.
Application 16/911,028 is a continuation of application No. 16/852,189, filed on Apr. 17, 2020, granted, now 10,780,125, issued on Sep. 22, 2020.
Application 16/852,189 is a continuation of application No. 16/750,908, filed on Jan. 23, 2020, granted, now 10,668,100, issued on Jun. 2, 2020.
Application 16/750,908 is a continuation of application No. 16/422,335, filed on May 24, 2019, granted, now 10,596,196, issued on Mar. 24, 2020.
Application 16/422,335 is a continuation of application No. 15/686,679, filed on Aug. 25, 2017, granted, now 10,376,542, issued on Aug. 13, 2019.
Claims priority of provisional application 62/379,864, filed on Aug. 26, 2016.
Claims priority of application No. 10 2016 115 974.3 (DE), filed on Aug. 26, 2016.
Prior Publication US 2021/0401888 A1, Dec. 30, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 35/16 (2015.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C07K 7/00 (2006.01); C07K 16/18 (2006.01); C12N 15/115 (2010.01)
CPC C07K 14/70539 (2013.01) [A61K 35/16 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); C07K 14/4748 (2013.01); C07K 16/2833 (2013.01); C07K 16/3053 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/572 (2013.01); C07K 7/00 (2013.01); C07K 16/18 (2013.01); C12N 15/115 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/998 (2013.01)] 17 Claims
 
1. An isolated peptide consisting of the amino acid sequence GLAGGFGGPGFPV (SEQ ID NO: 1) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.